Skip to content

InMode Optimas

Save device

IPL multi-app platform · Platform hosting Lumecca + Diolaze + RF

Classification & configurations

Category group: Hair removal (diode, alexandrite, Nd:YAG, IPL)

Current

At a glance

New price
$90k–$130kSource not documented
Used asking price
$40k–$70kSource not documented
FDA status
Supplies & recurring costs
See supply and replacement costs below.
View supply details
Sources and verified data on file

Data on file

Recurring consumables
Not verified
Used asking prices
Not verified
  • This panel shows a per-treatment supply cost only when a recorded figure has a dated source.
  • Bottle prices and estimates may still appear under Treatment & running costs.
  • The calculator may include a labeled planning estimate. Review it or enter your own allowance; missing data never means $0.

Figures are reference points, not current offers. Used asking prices are not completed-sale values.

Read FDA-cleared indicationsExact wording from 5 FDA records

K123860 (Inmode MD, Ltd., 2013)

The InMode SR IPL Device wavelengths (515-l200nm) are indicated for use for the following treatments: " The treatment of benign pigmented epidermal lesions, including dyschromia, hyperpigmentation, melasma, ephelides (freckles); " The treatment of benign cutaneous vascular lesions, including port wine stains, facial, truncal and leg telangiectasias, rosacea, erythema of rosacea, angiomas and spider angiomas, poikilodenna of Civatte, superficial leg veins and venlous malformations.

Verbatim from the FDA 510(k) summary, retrieved 8 Sep 2026.

K170738 (Inmode MD, Ltd., 2017)

The InMode Diolaze XL System is intended for hair removal and permanent hair reduction defined as the stable, long-term reduction in hair counts at 6, 9, or 12 months following a treatment regime.

Verbatim from the FDA 510(k) summary, retrieved 8 Sep 2026.

K173677 (Inmode MD, Ltd., 2018)

The InMode VLaze is intended for the treatment of vascular lesions, including angiomas, hemangiomas, telangiectasia, port wine stains, leg veins and other benign vascular lesions.

Verbatim from the FDA 510(k) summary, retrieved 8 Sep 2026.

K151273 (Inmode MD, Ltd., 2016)

The InMode FRF Applicator is intended for use in Dermatologic and General Surgical procedures for Electrocoagulation and Hemostasis . At higher energy levels greater than 62 mJ/pin, use of the FRF applicator is limited to Skin Types I-IV.

Verbatim from the FDA 510(k) summary, retrieved 8 Sep 2026.

K140926 (Inmode MD, Ltd., 2014)

The InMode WMface device is intended for use in dermatologic procedures for noninvasive treatment of mild to moderate facial wrinkles and rhytides.

Verbatim from the FDA 510(k) summary, retrieved 8 Sep 2026.

Page updated: September 8, 2026 · How we verify

New and used price references
New$90k–$130k
Source not documented
Used$40k–$70k
Source not documented

Axis runs $0–$130k. Reference figures, not current offers. Used asking prices are not completed-sale values.

Consumable cost per treatment

Not verified

We hold no per-treatment consumable price for this device from a dated source. Ask the seller for a written per-treatment cost.

Price sourcesSources, dates and configurations
New: $90k–$130k·Researched estimate — no dated source on file yet; not a quote.
Used asking range: $40k–$70k·Researched estimate — no dated source on file yet; not a quote.
Key factsCompany, specifications and verification dates
Key facts
ManufacturerInMode
CompanyOwner: Publicly traded (NASDAQ: INMD; no single controlling owner) (public company, since 2019) · Distribution: direct
Parent companyInMode
Brand ownerInMode
Built by (OEM)InMode Ltd.
CategoryIPL multi-app platform
TechnologyPlatform hosting Lumecca + Diolaze + RF
FDA statusFDA Cleared
510(k) citationK123860, K170738, K173677, K151273, K140926
New price range$90k–$130k
Used asking range$40k–$70k
ConsumablesNot published
Launch year2017
PricingNot published
Manufacturer-source documents checkedNot published

Overview

Workstation for IPL and diode HR

How it worksTechnology and manufacturing

How the technology works

A chassis powering interchangeable optical and RF handpieces. Lumecca is high-peak-power IPL (roughly 515/580nm cutoffs) targeting melanin and hemoglobin — sun damage, lentigines, rosacea, telangiectasia; InMode's pitch is higher peak power clears pigment in 1-2 sessions versus 3-5 for commodity IPLs.

Diolaze XL is a large-spot diode (810nm core; 755/810 and 810/1064 blends) for hair removal with contact cooling. Both non-invasive, no downtime.

Patented technology

Lumecca is branded high-peak-power IPL — a xenon flashlamp with tighter pulse control, not a new physics category. Diolaze XL's claim is one of the larger diode spots on the market plus built-in cooling — refined diode engineering.

Origin

Yokneam, Israel (InMode).

FDA & regulatory detailClearance timeline, authorization route and citation notes
Documented clearance timeline
Documented dates: Launch 2017, Clearance 201820172018

Launch 2017 · Clearance 2018 · K123860; K170738; K173677; K151273; K140926

Authorized via 510(k)

Platform clearance: FDA's device listing carries 'CONTOURA/OPTIMAS (system platform)' with the SR IPL/Lumecca (K123860, 2 Apr 2013), Diolaze XL (K170738, 7 Aug 2017), VLaze/Vasculaze (K173677, 23 Feb 2018), FRF/Fractora (K151273, 4 Jan 2016) and WMFace/Forma (K140926, 3 Dec 2014) applicators; no 510(k) naming Optimas was located (the 2025 Optimas MAX is a separate record, K251632). Checked 8 Sep 2026.

FDA-cleared indications (verbatim)

K123860 (Inmode MD, Ltd., 2013)

The InMode SR IPL Device wavelengths (515-l200nm) are indicated for use for the following treatments: " The treatment of benign pigmented epidermal lesions, including dyschromia, hyperpigmentation, melasma, ephelides (freckles); " The treatment of benign cutaneous vascular lesions, including port wine stains, facial, truncal and leg telangiectasias, rosacea, erythema of rosacea, angiomas and spider angiomas, poikilodenna of Civatte, superficial leg veins and venlous malformations.

Verbatim from the FDA 510(k) summary, retrieved 8 Sep 2026.

K170738 (Inmode MD, Ltd., 2017)

The InMode Diolaze XL System is intended for hair removal and permanent hair reduction defined as the stable, long-term reduction in hair counts at 6, 9, or 12 months following a treatment regime.

Verbatim from the FDA 510(k) summary, retrieved 8 Sep 2026.

K173677 (Inmode MD, Ltd., 2018)

The InMode VLaze is intended for the treatment of vascular lesions, including angiomas, hemangiomas, telangiectasia, port wine stains, leg veins and other benign vascular lesions.

Verbatim from the FDA 510(k) summary, retrieved 8 Sep 2026.

K151273 (Inmode MD, Ltd., 2016)

The InMode FRF Applicator is intended for use in Dermatologic and General Surgical procedures for Electrocoagulation and Hemostasis . At higher energy levels greater than 62 mJ/pin, use of the FRF applicator is limited to Skin Types I-IV.

Verbatim from the FDA 510(k) summary, retrieved 8 Sep 2026.

K140926 (Inmode MD, Ltd., 2014)

The InMode WMface device is intended for use in dermatologic procedures for noninvasive treatment of mild to moderate facial wrinkles and rhytides.

Verbatim from the FDA 510(k) summary, retrieved 8 Sep 2026.

Marketed for

IPL multi-app platform — Platform hosting Lumecca + Diolaze + RF

Marketing claims are the manufacturer's own and are not the same as a cleared indication.

Parent company: InMode

Legal manufacturer: InMode Ltd. (Israel)

Applicant on the FDA record

InMode MD Ltd.The applicant named on the FDA record can differ from the brand shown on the device.

Regulatory data comes from public FDA records and may lag recent updates. Confirm the applicable status and documentation before purchase.

Treatment & running costs

Treatments

Sessions & timing

No treatment schedule documented yet.

What practices charge

No sourced treatment price on file.

Supplies & recurring costs

Supply pricing is not documented with a dated source yet. Request an itemized supply quote.

Annual service & support

No annual service cost documented yet.

Payback calculatorModel your own volume, labor and service costs

Estimate your payback

Pre-filled from our published InMode Optimas data where we have it. Estimates appear once the required inputs are available. Review and adjust every pre-filled value before relying on the result.

Start from

No verified per-treatment supply cost is on file. Enter your own allowance. Use $0 only if you have confirmed that it applies to your practice.

Pre-filled from the midpoint of the published new-price range

20 is an illustrative default — change it to your volume.

No sourced per-session price on file — enter what you charge.

Required — enter your cost; missing data does not mean $0.

Provider or tech time for one treatment, fully loaded. Enter 0 if you own-operate.

Annual service contract ÷ 12, if you carry one.

Your estimate

Enter price you charge per treatment, consumable cost per treatment to see contribution and a payback range.

This model ignores financing — if you lease or borrow, add your monthly payment. Estimates from your inputs and our published ranges — not a projection, guarantee or financial advice. How we calculate this.

ComplianceScreening and contraindications on the manufacturer's record

Contraindications & screening

Recent tanning or active melasma flare (IPL), pregnancy, photosensitizers, active infection/lesions in the field, keloid history, darker Fitzpatrick types on the 810-only handpiece.

Warranty & serviceWhat to confirm in writing before you buy

Before buying new or used, confirm in writing:

  • Current warranty coverage
  • Included training
  • Service terms

Chains using this device

A chain listing does not establish availability at every location.

No confirmed chain deployments recorded yet.

Owner & operator reviews

Write a review

No owner or operator reviews yet. Be the first →

Current alternatives

Current catalog models to research. Confirm availability and configuration with the supplier.

InMode Envision

IPL multi-app platform

Venus Versa Pro

IPL multi-app platform · $100k–$130k

History4 tracked changes

Every tracked change to pricing, lifecycle status, FDA data and warranty terms — newest first.

  1. September 8, 2026

    FDA status

    UnknownCleared

    Source: Record correction

  2. September 8, 2026

    FDA K-numbers

    K123860; K170738; K173677; K151273; K140926

    Source: Record correction

  3. September 8, 2026

    FDA source URL

    https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K123860

    Source: Record correction

  4. August 1, 2026

    Record created

    Added to The Aesthetic Index — August 2026

    Source: The Aesthetic Index editorial

Cite this data: The Aesthetic Index, "InMode Optimas — pricing, FDA status and cost to own", aestheticindex.co (accessed September 24, 2026).

Get the full State of Aesthetic Devices 2026 report

A catalog of US-marketed aesthetic and wellness devices — preview it free.

Get the report

Device and company names are trademarks of their respective owners. The Aesthetic Index is not affiliated with or endorsed by any manufacturer, distributor or lender named here, except as disclosed. Price figures are references, not current offers. Check each device’s source notes. Not medical, legal or regulatory advice.